MapLight Raises $150 M PIPE To Fund CNS Pipeline
MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.
How this was made
The 30-second read
Why it matters
The $150M PIPE increases liquidity and extends funding through 2028, but the fixed issuance at $11.38 introduces dilution overhang that can pressure the stock until investors model the updated capital needs and trial timelines.
Market read
Traders can reassess dilution and financing risk ahead of the August 14 close, using the disclosed pricing, share counts, and stated cash runway through 2028.
What to watch
The article does not state whether the PIPE includes any investor lockups, resale restrictions, or whether the pre-funded warrants materially change effective dilution versus common issuance.
Background
MapLight is advancing CNS programs including an Alzheimer’s disease psychosis Phase 2 study (VISTA) and a schizophrenia Phase 3 registrational study (ZEPHYR-2), with an FDA End-of-Phase 2 meeting planned.
Ticker impact
MapLight priced a $150M PIPE, issuing 9.2M shares at $11.38 and funding CNS trials including VISTA Phase 2 and ZEPHYR-2 Phase 3.
Likely near-term volatility with a bias to downside from dilution, partially offset by improved funding visibility through 2028.
The article discloses deal size, pricing, share count, and stated cash runway, which directly affects dilution expectations and perceived financing risk.
Market effects
CNS biotech financing conditions may remain active, but PIPE pricing can signal investor selectivity for late-stage trial funding.
No specific regional market linkage beyond US biotech capital markets.
Limited direct global impact; primarily affects MapLight’s capital structure and trial funding.
Counterpoint
If the PIPE price is viewed as reasonable relative to the company’s cash runway and upcoming FDA End-of-Phase 2 milestone, the financing could be interpreted as de-risking rather than dilutive pressure.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the PIPE financing used to fund ML-007C-MA clinical development and FDA Phase 3 design discussions.
- drug_programML-007C-MA
Lead CNS candidate referenced as the primary use of proceeds.
- clinical_trialVISTA Phase 2 (Alzheimer’s disease psychosis)
Phase 2 study expected to be advanced with PIPE proceeds.
- clinical_trialZEPHYR-2 Phase 3 (schizophrenia)
Registrational Phase 3 study expected to be advanced with PIPE proceeds.
- regulatory_milestoneFDA End-of-Phase 2 meeting
Planned engagement to finalize Phase 3 trial design for schizophrenia.